Sign in
Taking people in PolandPhase 1

Tests anifrolumab in adults with systemic lupus erythematosus

Tests how safe anifrolumab is and how the body handles it in adults with lupus.

Key facts

Who runs it
AstraZeneca AB
Where
Bydgoszcz, Cracow, Katowice, Poznan, and Warsaw, PolandSee the 6 sitesAlso in 1 other country, 1 site
Registry title
A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus
Status
Recruiting
Phase
Phase 1
People taking part
13 people, planned
Started
23 Oct 2026
Expected to end
13 Feb 2031
Type of study
Interventional
Record updated
25 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with systemic lupus erythematosus. It studies how safe anifrolumab is and how it moves through the body.

Age
18 years or older
Sex
All sexes can join.

Where in Poland

Also in 1 other country, 1 site

  • Szpital Uniwersytecki nr 2 im dr Jana Biziela w BydgoszczyBydgoszcz, PolandTaking people
  • Promed P.Lach R.Glowacki Sp. j.Cracow, PolandTaking people
  • Provita Sp z o oKatowice, PolandTaking people
  • Ai Centrum Medyczne Sp. Z O.O.Poznan, PolandTaking people
  • Klinika Reuma Park Sp. z o.o. S.K.Warsaw, PolandTaking people
  • Medicover Integrated Clinical Services Sp. z o.o.Warsaw, PolandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests anifrolumab in adults with systemic lupus erythematosusGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
25 September 2026